Header Logo

Connection

Jeffrey Kordower to Male

Back to Details
This is a "connection" page, showing publications Jeffrey Kordower has written about Male.
Jeffrey Kordower
Connection Strength
1.363
Male
  1. In situ proximity labeling identifies Lewy pathology molecular interactions in the human brain. Proc Natl Acad Sci U S A. 2022 02 01; 119(5).
    View in: PubMed
    Score: 0.060
  2. GDNF signaling in subjects with minimal motor deficits and Parkinson's disease. Neurobiol Dis. 2021 06; 153:105298.
    View in: PubMed
    Score: 0.056
  3. Do subjects with minimal motor features have prodromal Parkinson disease? Ann Neurol. 2018 03; 83(3):562-574.
    View in: PubMed
    Score: 0.046
  4. Induction of alpha-synuclein pathology in the enteric nervous system of the rat and non-human primate results in gastrointestinal dysmotility and transient CNS pathology. Neurobiol Dis. 2018 04; 112:106-118.
    View in: PubMed
    Score: 0.045
  5. Novel oligodendroglial alpha synuclein viral vector models of multiple system atrophy: studies in rodents and nonhuman primates. Acta Neuropathol Commun. 2017 06 16; 5(1):47.
    View in: PubMed
    Score: 0.044
  6. Parkinsonian monkeys with prior levodopa-induced dyskinesias followed by fetal dopamine precursor grafts do not display graft-induced dyskinesias. J Comp Neurol. 2017 02 15; 525(3):498-512.
    View in: PubMed
    Score: 0.041
  7. Alterations in Activity-Dependent Neuroprotective Protein in Sporadic and Experimental Parkinson's Disease. J Parkinsons Dis. 2016; 6(1):77-97.
    View in: PubMed
    Score: 0.039
  8. Abnormal alpha-synuclein reduces nigral voltage-dependent anion channel 1 in sporadic and experimental Parkinson's disease. Neurobiol Dis. 2014 Sep; 69:1-14.
    View in: PubMed
    Score: 0.035
  9. Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson's disease. Mov Disord. 2014 Jul; 29(8):999-1009.
    View in: PubMed
    Score: 0.034
  10. In memorium: Roy A.E. Bakay, MD. Mov Disord. 2013 Nov; 28(13):1809-10.
    View in: PubMed
    Score: 0.034
  11. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain. 2013 Aug; 136(Pt 8):2419-31.
    View in: PubMed
    Score: 0.033
  12. Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease. Brain. 2012 Jul; 135(Pt 7):2058-73.
    View in: PubMed
    Score: 0.031
  13. Is alpha-synuclein in the colon a biomarker for premotor Parkinson's disease? Evidence from 3 cases. Mov Disord. 2012 May; 27(6):716-9.
    View in: PubMed
    Score: 0.031
  14. Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease. Mov Disord. 2012 May; 27(6):709-15.
    View in: PubMed
    Score: 0.029
  15. Transfer of host-derived a synuclein to grafted dopaminergic neurons in rat. Neurobiol Dis. 2011 Sep; 43(3):552-7.
    View in: PubMed
    Score: 0.029
  16. Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov Disord. 2011 Jan; 26(1):27-36.
    View in: PubMed
    Score: 0.028
  17. a-synuclein aggregation reduces nigral myocyte enhancer factor-2D in idiopathic and experimental Parkinson's disease. Neurobiol Dis. 2011 Jan; 41(1):71-82.
    View in: PubMed
    Score: 0.027
  18. Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates. Mol Ther. 2010 Mar; 18(3):579-87.
    View in: PubMed
    Score: 0.025
  19. Injectable hydrogels providing sustained delivery of vascular endothelial growth factor are neuroprotective in a rat model of Huntington's disease. Neurotox Res. 2010 Jan; 17(1):66-74.
    View in: PubMed
    Score: 0.025
  20. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiol Dis. 2009 Sep; 35(3):385-98.
    View in: PubMed
    Score: 0.025
  21. Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. Mov Disord. 2008 Dec 15; 23(16):2303-6.
    View in: PubMed
    Score: 0.024
  22. Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington's disease. Neurobiol Dis. 2007 May; 26(2):375-84.
    View in: PubMed
    Score: 0.021
  23. Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann Neurol. 2006 Dec; 60(6):706-15.
    View in: PubMed
    Score: 0.021
  24. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease? Neurobiol Dis. 2007 Jan; 25(1):134-49.
    View in: PubMed
    Score: 0.021
  25. Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys. Ann Neurol. 2006 Aug; 60(2):264-8.
    View in: PubMed
    Score: 0.020
  26. Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease. Proc Natl Acad Sci U S A. 2006 Jun 13; 103(24):9345-50.
    View in: PubMed
    Score: 0.020
  27. Nurr1 in Parkinson's disease and related disorders. J Comp Neurol. 2006 Jan 20; 494(3):495-514.
    View in: PubMed
    Score: 0.020
  28. Proximity proteomics reveals unique and shared pathological features between multiple system atrophy and Parkinson's disease. Acta Neuropathol Commun. 2025 Mar 23; 13(1):65.
    View in: PubMed
    Score: 0.019
  29. Human neural stem cell transplants improve motor function in a rat model of Huntington's disease. J Comp Neurol. 2004 Jul 19; 475(2):211-9.
    View in: PubMed
    Score: 0.018
  30. Structural and functional neuroprotection in a rat model of Huntington's disease by viral gene transfer of GDNF. Exp Neurol. 2003 Jun; 181(2):213-23.
    View in: PubMed
    Score: 0.016
  31. Knockout of p75NTR does not alter the viability of striatal neurons following a metabolic or excitotoxic injury. J Mol Neurosci. 2003 Apr; 20(2):93-102.
    View in: PubMed
    Score: 0.016
  32. Age-related decreases in Nurr1 immunoreactivity in the human substantia nigra. J Comp Neurol. 2002 Aug 26; 450(3):203-14.
    View in: PubMed
    Score: 0.016
  33. Excitotoxic and metabolic damage to the rodent striatum: role of the P75 neurotrophin receptor and glial progenitors. J Comp Neurol. 2002 Mar 18; 444(4):291-305.
    View in: PubMed
    Score: 0.015
  34. Loss of basal forebrain P75(NTR) immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease. J Comp Neurol. 2002 Feb 04; 443(2):136-53.
    View in: PubMed
    Score: 0.015
  35. Behavioral and morphological comparison of two nonhuman primate models of Huntington's disease. Neurosurgery. 2002 Jan; 50(1):137-45; discussion 145-6.
    View in: PubMed
    Score: 0.015
  36. Anti-a-synuclein ASO delivered to monoamine neurons prevents a-synuclein accumulation in a Parkinson's disease-like mouse model and in monkeys. EBioMedicine. 2020 Sep; 59:102944.
    View in: PubMed
    Score: 0.014
  37. Striatal Nurr1 Facilitates the Dyskinetic State and Exacerbates Levodopa-Induced Dyskinesia in a Rat Model of Parkinson's Disease. J Neurosci. 2020 04 29; 40(18):3675-3691.
    View in: PubMed
    Score: 0.013
  38. Human autologous iPSC-derived dopaminergic progenitors restore motor function in Parkinson's disease models. J Clin Invest. 2020 02 03; 130(2):904-920.
    View in: PubMed
    Score: 0.013
  39. T cell infiltration in both human multiple system atrophy and a novel mouse model of the disease. Acta Neuropathol. 2020 05; 139(5):855-874.
    View in: PubMed
    Score: 0.013
  40. Widespread Striatal Delivery of GDNF from Encapsulated Cells Prevents the Anatomical and Functional Consequences of Excitotoxicity. Neural Plast. 2019; 2019:6286197.
    View in: PubMed
    Score: 0.012
  41. Demonstration of prion-like properties of mutant huntingtin fibrils in both in vitro and in vivo paradigms. Acta Neuropathol. 2019 06; 137(6):981-1001.
    View in: PubMed
    Score: 0.012
  42. Analysis of age-related changes in psychosine metabolism in the human brain. PLoS One. 2018; 13(2):e0193438.
    View in: PubMed
    Score: 0.011
  43. Probing the striatal dopamine system for a putative neuroprotective effect of deep brain stimulation in Parkinson's disease. Mov Disord. 2018 04; 33(4):652-654.
    View in: PubMed
    Score: 0.011
  44. Presence of tau pathology within foetal neural allografts in patients with Huntington's and Parkinson's disease. Brain. 2017 Nov 01; 140(11):2982-2992.
    View in: PubMed
    Score: 0.011
  45. The Potential Role of Gut-Derived Inflammation in Multiple System Atrophy. J Parkinsons Dis. 2017; 7(2):331-346.
    View in: PubMed
    Score: 0.011
  46. Mitochondrial pyruvate carrier regulates autophagy, inflammation, and neurodegeneration in experimental models of Parkinson's disease. Sci Transl Med. 2016 12 07; 8(368):368ra174.
    View in: PubMed
    Score: 0.011
  47. Neutralization of RANTES and Eotaxin Prevents the Loss of Dopaminergic Neurons in a Mouse Model of Parkinson Disease. J Biol Chem. 2016 07 15; 291(29):15267-81.
    View in: PubMed
    Score: 0.010
  48. Evaluation of alpha-synuclein immunohistochemical methods for the detection of Lewy-type synucleinopathy in gastrointestinal biopsies. Acta Neuropathol Commun. 2016 Apr 04; 4:35.
    View in: PubMed
    Score: 0.010
  49. Broad distribution of ataxin 1 silencing in rhesus cerebella for spinocerebellar ataxia type 1 therapy. Brain. 2015 Dec; 138(Pt 12):3555-66.
    View in: PubMed
    Score: 0.010
  50. PGC-1a Promoter Methylation in Parkinson's Disease. PLoS One. 2015; 10(8):e0134087.
    View in: PubMed
    Score: 0.010
  51. Analysis of YFP(J16)-R6/2 reporter mice and postmortem brains reveals early pathology and increased vulnerability of callosal axons in Huntington's disease. Hum Mol Genet. 2015 Sep 15; 24(18):5285-98.
    View in: PubMed
    Score: 0.010
  52. Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. Ann Neurol. 2015 Aug; 78(2):248-57.
    View in: PubMed
    Score: 0.009
  53. Neonatal immune-tolerance in mice does not prevent xenograft rejection. Exp Neurol. 2014 Apr; 254:90-8.
    View in: PubMed
    Score: 0.009
  54. A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease. Alzheimers Dement. 2014 Sep; 10(5):571-81.
    View in: PubMed
    Score: 0.009
  55. In vivo evaluation of [(123)I]MNI-420: a novel single photon emission computed tomography radiotracer for imaging of adenosine 2A receptors in brain. Nucl Med Biol. 2013 Apr; 40(3):403-9.
    View in: PubMed
    Score: 0.008
  56. Enduring cortical alterations after a single in-vivo treatment of HIV-1 Tat. Neuroreport. 2012 Oct 03; 23(14):825-9.
    View in: PubMed
    Score: 0.008
  57. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. PLoS One. 2011; 6(12):e28032.
    View in: PubMed
    Score: 0.007
  58. Prenatal exposure to MDMA alters noradrenergic neurodevelopment in the rat. Neurotoxicol Teratol. 2012 Jan-Feb; 34(1):206-13.
    View in: PubMed
    Score: 0.007
  59. Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease. Neurobiol Dis. 2011 Oct; 44(1):38-52.
    View in: PubMed
    Score: 0.007
  60. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2010 Dec; 9(12):1164-1172.
    View in: PubMed
    Score: 0.007
  61. ?-Secretase-1 elevation in aged monkey and Alzheimer's disease human cerebral cortex occurs around the vasculature in partnership with multisystem axon terminal pathogenesis and ?-amyloid accumulation. Eur J Neurosci. 2010 Oct; 32(7):1223-38.
    View in: PubMed
    Score: 0.007
  62. Decreased alpha-synuclein expression in the aging mouse substantia nigra. Exp Neurol. 2009 Dec; 220(2):359-65.
    View in: PubMed
    Score: 0.006
  63. Response of aged parkinsonian monkeys to in vivo gene transfer of GDNF. Neurobiol Dis. 2009 Nov; 36(2):303-11.
    View in: PubMed
    Score: 0.006
  64. Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis. Mov Disord. 2009 Feb 15; 24(3):336-43.
    View in: PubMed
    Score: 0.006
  65. Doublecortin expression in adult cat and primate cerebral cortex relates to immature neurons that develop into GABAergic subgroups. Exp Neurol. 2009 Apr; 216(2):342-56.
    View in: PubMed
    Score: 0.006
  66. Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum. Mol Ther. 2008 Oct; 16(10):1737-44.
    View in: PubMed
    Score: 0.006
  67. Age-related changes in glial cells of dopamine midbrain subregions in rhesus monkeys. Neurobiol Aging. 2010 Jun; 31(6):937-52.
    View in: PubMed
    Score: 0.006
  68. Postmortem study of deep brain stimulation of the anterior thalamus: case report. Neurosurgery. 2008 Feb; 62(2):E530-2; discussion E532.
    View in: PubMed
    Score: 0.006
  69. Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A. 2007 Nov 20; 104(47):18754-9.
    View in: PubMed
    Score: 0.006
  70. Age-related accumulation of Marinesco bodies and lipofuscin in rhesus monkey midbrain dopamine neurons: relevance to selective neuronal vulnerability. J Comp Neurol. 2007 Jun 10; 502(5):683-700.
    View in: PubMed
    Score: 0.005
  71. AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease. Neurobiol Dis. 2007 Jul; 27(1):67-76.
    View in: PubMed
    Score: 0.005
  72. Role of heparin binding growth factors in nigrostriatal dopamine system development and Parkinson's disease. Brain Res. 2007 May 25; 1147:77-88.
    View in: PubMed
    Score: 0.005
  73. Proteasome inhibition and Parkinson's disease modeling. Ann Neurol. 2006 Aug; 60(2):260-4.
    View in: PubMed
    Score: 0.005
  74. Age-related alterations in GABA(A) receptor subunits in the nonhuman primate hippocampus. Brain Res. 2006 Feb 16; 1073-1074:120-30.
    View in: PubMed
    Score: 0.005
  75. Substantia nigra tangles are related to gait impairment in older persons. Ann Neurol. 2006 Jan; 59(1):166-73.
    View in: PubMed
    Score: 0.005
  76. Focal not widespread grafts induce novel dyskinetic behavior in parkinsonian rats. Neurobiol Dis. 2006 Jan; 21(1):165-80.
    View in: PubMed
    Score: 0.005
  77. Early changes in Huntington's disease patient brains involve alterations in cytoskeletal and synaptic elements. J Neurocytol. 2004 Sep; 33(5):517-33.
    View in: PubMed
    Score: 0.004
  78. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol. 2003 Sep; 54(3):403-14.
    View in: PubMed
    Score: 0.004
  79. Prenatal 3,4-methylenedioxymethamphetamine (ecstasy) alters exploratory behavior, reduces monoamine metabolism, and increases forebrain tyrosine hydroxylase fiber density of juvenile rats. Neurotoxicol Teratol. 2003 Sep-Oct; 25(5):509-17.
    View in: PubMed
    Score: 0.004
  80. Distribution of high affinity choline transporter immunoreactivity in the primate central nervous system. J Comp Neurol. 2003 Aug 25; 463(3):341-57.
    View in: PubMed
    Score: 0.004
  81. Inhibitors of cyclooxygenase-2, but not cyclooxygenase-1 provide structural and functional protection against quinolinic acid-induced neurodegeneration. J Pharmacol Exp Ther. 2003 Jul; 306(1):218-28.
    View in: PubMed
    Score: 0.004
  82. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol. 2002 Feb; 51(2):145-55.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.